Optimized, response-based dosing of ICLUSIG (ponatinib) in CP-CML
OPTIC 5-YEAR TRIAL DATA
45 mg → 15 mg for patients who achieve ≤1% BCR::ABL1IS
The ICLUSIG OPTIC trial established an response-based dosing strategy in CP-CML1,2
View the optimized dosing strategy for CP-CMLSee how optimized, response-based dosing with ICLUSIG may help patients with CP-CML
ShowHide Transcript
[00:00:00.120] For adult patients with newly diagnosed Ph+ ALL or patients facing resistant
[00:00:05.480] or intolerant CP-CML, there is a high probability of developing mutations
[00:00:10.560] in BCR::ABL1. Mutations can lead to resistance and are the primary cause of relapse
[00:00:16.160] in patients in newly diagnosed Ph+ ALL.
[00:00:19.840] Prescribing an effective first-line treatment is critical to achieving MRD-negative
[00:00:24.920] CR at the end of induction in CML.
[00:00:27.640] Early identification of resistant mutations, including T315I,
[00:00:32.400] one of the most frequently identified,
[00:00:34.680] is crucial to informing your patients' next line of treatment.
[00:00:38.440] ICLUSIG is the first and only FDA-approved TKI for adults with newly diagnosed
[00:00:44.160] Ph+ ALL in combination with chemotherapy,
[00:00:47.560] and is also approved for adult patients with CP-CML with the T315I mutation
[00:00:53.595] or with resistance or intolerance to at least two prior TKIs.
[00:00:58.148] ICLUSIG was designed to bind across the BCR::ABL1 mutation spectrum,
[00:01:03.068] including T315I. ICLUSIG was designed with response-based dosing to help physicians
[00:01:08.988] optimize treatment based on individual patient response.
[00:01:12.708] For newly diagnosed Ph+ ALL, follow response-based dosing in combination
[00:01:18.108] with chemotherapy. Start with 30 mg,
[00:01:21.108] reduce to 15 mg in patients who achieve negative CR at the end of induction,
[00:01:26.388] and maintain for up to 20 cycles until loss of response or unacceptable toxicity.
[00:01:32.108] For patients with CP-CML who are resistant or intolerant to at least two prior TKIs,
[00:01:37.748] follow response-based dosing. Start at 45 mg to establish efficacy and reduce
[00:01:43.508] to 15 mg upon achieving less than or equal to 1% BCR::ABL1.
[00:01:49.068] Maintain on 15 mg as long as response is maintained.
[00:01:52.988] ICLUSIG is supported by Takeda Oncology Here2Assist®,
[00:01:56.868] here to help your patients with coverage and access, financial assistance,
[00:02:00.988] and educational resources. To enroll your patients and access coverage tools,
[00:02:05.908] sample letters, and copay support, contact a Here2Assist® Case Manager.
[00:02:10.588] Start strong with ICLUSIG for patients with newly diagnosed Ph+ ALL.
[00:02:16.308] Early identification of resistance is crucial to helping resistant or intolerant CP-CML.
To maximize efficacy and manage tolerability of ICLUSIG,
follow these three steps:
Start with 45 mg
Start at 45 mg to establish efficacy.
- Start at 30 mg orally once daily in patients taking strong CYP3A inhibitors and in patients with pre-existing hepatic impairment (Child-Pugh A, B, or C).
Reduce to 15 mg
Reduce the dose to 15 mg orally once daily after ≤1% BCR::ABL1IS is achieved, to manage tolerability.
- In the OPTIC trial, of the 93 patients who received ICLUSIG 45 mg → 15 mg, 52 achieved ≤1% BCR::ABL1IS at any time.
- Consider discontinuing ICLUSIG if hematologic response has not occurred by 3 months.
Maintain at 15 mg
Patients can continue with the 15 mg, once-daily dose of ICLUSIG for as long as they maintain response.
- Patients who lose response can have their dose re-escalated to a previously tolerated dosage of 30 mg or 45 mg orally once daily.
- Of the 52 patients who achieved ≤1% BCR::ABL1IS at any time, 13 patients lost response and had their dose re-escalated.
- 62% of these patients (n=8/13) regained response following dose re-escalation.
- Patients taking 15 mg orally once daily who experience an adverse reaction can have their dose reduced to 10 mg orally once daily once the adverse reaction resolves.